BG Medicine to Find Biomarkers, Study Drug Effects in Deal with Boehringer Ingelheim

Jul 28, 2005

NEW YORK, July 28 (GenomeWeb News) - Using its systems pharmacology platform, BG Medicine will examine the effects of drugs in tissue and discover plasma biomarkers in an agreement with Boehringer Ingelheim Pharmaceuticals, the companies said today in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Silencing for Preeclampsia

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

Settlement Expected in Duke Case

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

This Week in PNAS

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

Something Different

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.

Main menu